• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • China vaccine production and distribution rules released

China vaccine production and distribution rules released

china-vaccine-production
Wednesday, 10 August 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

China vaccine production and distribution rules released

China Vaccine Production and Distribution Rules were released by the National Medical Products Administration (NMPA) on July 8, 2022 and came into effect immediately. 

The new Rules on the Administration of Vaccine Manufacturing and Distribution (“RAVMD”) is a more detailed implementation regulation on vaccine production, distribution, change and supervision based on the Vaccine Administration Law (VAL).

The China Vaccine Production & Distribution Rules contain a total of 7 chapters (44 articles in total), and the main contents are summarized below.

Production requirements

Marketing Authorization Holders (MAH) shall be primarily responsible for the safety, efficacy and quality control of vaccines. The MAH should have full capacity for the vaccine production. If the required production capacity exceeds the MAH’s vaccine production capacity, the MAH can apply to the NMPA for entrusted production, but one of the following three conditions needs to be satisfied:

  • The industry and information management department of the State Council requests the creation of vaccine reserves, and believes that the holder’s existing production capacity cannot satisfy the requirements;
  • The health management department of the State Council proposes an urgent need for disease prevention and control, and believes that the current production capacity of the holder cannot satisfy the requirements;
  • Production of polyvalent vaccines.

If you would like to know about the application process for entrusted vaccine production (including application dossier requirements, acceptance, review and approval), please contact us for more information.

Vaccine circulation management

Provincial disease prevention and control institutions are responsible for formulating vaccine use plans in their administrative regions, and vaccine marketing license holders are responsible for distributing vaccines to disease prevention and control institutions or to inoculation units designated by disease prevention and control institutions.

In principle, overseas vaccine holders should designate a domestic drug wholesale enterprise with cold chain drug quality assurance capabilities to sell their vaccines of the same variety uniformly.

Marketing license holders can entrust enterprises to distribute and store vaccines in regions as long as the entrusted distribution enterprise meets the transportation and storage conditions of refrigerated and frozen medicines in accordance with the Quality Management Standards for Pharmaceuticals.

In principle, the marketing license holder may not select more than 2 vaccine regional distribution companies within the same provincial administrative region.

Companies that accept entrusted distribution are not allowed to recommission.

In the process of circulation management of imported vaccines, if major deviations or major quality problems that may affect the quality of vaccine products are found, the domestic agent designated by the overseas vaccine holder shall report to the provincial drug supervision and administration department where the port of importation is located.

Other provisions

The state implements a strict access system for vaccine production and strictly controls the opening of new vaccine manufacturing enterprises. This means that under the new regulatory environment, the entry barriers for companies to obtain production licenses will be stricter.

The final chapter of RAVMD specifies that vaccines that have been exported from China are prohibited from being re-imported into the country. It also further explained that when overseas vaccine holders entrust Chinese enterprises to manufacture vaccines, the vaccines should be registered domestically as localized products instead of imported products. Meaning that a domestic owner should be designated in advance to apply for the registration.

Further information

Please access the full rules on China vaccine production and distribution here:
https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20220708185734126.html

If you would like more information on vaccine production and distribution in China or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods, please contact us.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

Simplifications of Clinical Studies
china gb 4943.1-2022 safety requirement
China GB 4943.1-2022 safety requirements for audio/video, information and communication technology equipment issued
Medical device classification catalogue
Medical Device Classification Catalogue Changes in March 2022

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.